Anti-JAM-A Antibody (FITC) (Mouse Monoclonal antibody) General Information
Anti-JAM-A Antibody (FITC)
Reacts with: Human
Recombinant Human JAM-A / F11R / CD321 protein (Catalog#10198-H08H)
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human JAM-A / F11R / CD321 (rh JAM-A / F11R / CD321; Catalog#10198-H08H; NP_058642.1; Met 1-Ala 242) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Monoclonal Mouse IgG1 Clone #04
Aqueous solution containing 0.5% BSA and 0.09% sodium azide
10 μl/Test, 0.1 mg/ml
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Anti-JAM-A Antibody (FITC) (Mouse Monoclonal antibody) Validated Applications
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-JAM-A Antibody (FITC) (Mouse Monoclonal antibody) Images
Profile of anti-JAM-A (CD321) reactivity on SKBR3 cells analyzed by flow cytometry.
Anti-JAM-A Antibody (FITC) Alternative Names
Anti-CD321 Antibody;Anti-JAM Antibody;Anti-JAM1 Antibody;Anti-JAMA Antibody;Anti-JCAM Antibody;Anti-KAT Antibody;Anti-PAM-1 Antibody
JAM-A Background Information
Junctional adhesion molecule-A (JAM-A), also known as F11 receptor (F11R) or Cluster of Differentiation 321 (CD321), is a transmembrane protein expressed at tight junctions of epithelial and endothelial cells, as well as on circulating leukocytes. JAM-A protein serves as a serotype-independent receptor for mammalian orthoreoviruses (reoviruses). It is also a ligand for the integrin LFA1, involves in leukocyte transmigration. As a cell adhesion molecule of the immunoglobulin superfamily, JAM-A protein involves in platelet adhesion, secretion and aggregation, and plays a crucial role in inflammatory thrombosis and atherosclerosis. In addition, it may be a potential therapeutic target for breast cancer.
Guglielmi KM, et al. (2007) Reovirus binding determinants in junctional adhesion molecule-A. J Biol Chem. 282(24): 17930-40.Yeung D, et al. (2008) Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathol. 115(6): 635-42.Ong KL, et al. (2009) Elevated plasma level of soluble F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) in hypertension. Am J Hypertens. 22(5): 500-5.